- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03758833
eSET or eDET Associated to PGT in IVF (SetDetPgt)
Single or Double Elective Embryos Transfer Associated to Preimplantation Genetic Test in in Vitro Fertilization Cycles
Study Overview
Status
Conditions
Detailed Description
Infertility is an important public health problem, affecting between 8 and 12% of reproductive-age couples, and leading to a high prevalence of childless couples (Bergstrom, 1992; Ombelet and Campo, 2007). The demand for infertility treatment is increasing due to sociocultural factors such as delayed pregnancy, higher incidence of sexually transmitted diseases, obesity rates, and greater acceptance to the available treatments. Recent estimates have shown that more than 1.8 million assisted reproduction treatments (ART) were performed in 2010 and more than 6 million children born were conceived using ART (Dyer et al., 2016).
In vitro fertilization (IVF) techniques have improved performance and currently provide a live embryo transfer rate that is around 25%. However, the success of IVF techniques depends on maximum efficiency in each treatment step, from controlled ovarian stimulation to obtaining adequate numbers of good quality mature eggs, optimal embryo culture conditions, availability of embryos of good quality for transfer and an adequate endometrium for implantation. Changes in clinical and laboratory practices such as the transfer of embryos in the blastocyst stage, improvement of cryopreservation techniques, transfer of thawed embryos after endometrial preparation and single embryo transfer (SET), have been increasingly indicated for patients with good prognosis. At the same time, the use of SET and freezing of all embryos for later transfer of thawed embryos are the major paradigms of ART in recent years (Chambers et al., 2016).
Despite a variation among countries influenced by coverage of health plans, legislation, guides to medical societies, population and culture, in Europe, on average 20% of transfers are single, with up to 69% of cycles in Sweden. In the United States, elective SET is still low, around 10% among women up to 35 years of age (Maheshwari et al., 2011; Practice Committee of the Society for Assisted Reproductive and Practice Committee of the American Society for Reproductive Medicine, 2012). Despite recommendations and increased SET practice, multiple gestation rates in IVF techniques are still high in the overall mean, around 20-25%, as a result of resistance of using SET and maintaining the transfer of multiple embryos with the purpose of obtaining higher gestation rates (Naasan et al., 2012, Kupka et al., 2014, Ishihara et al., 2015). This resistance is due to the idea that transferring more than one embryo may increase the chance of gestation. However, this practice does not take in consideration the increase of maternal and perinatal complications due to multiple pregnancies (Min et al., 2010; Practice Committee of American Society for Reproductive, 2012). In addition, studies have shown that cumulative live birth rates after the transfer of two SET cycles are comparable with a single transfer of two embryos (Pandian et al., 2009; Chambers and Ledger, 2014).
Historically, it is known that among the total number of retrieved oocytes, only a limited amount of them carry the potential to generate full-term gestation. Thus, embryo selection is a crucial step for the success of IVF techniques and the efficiency of this process is related to the decrease in the number of embryos to be transferred, since once it is possible to select embryos with greater implantation potential, the transfer of fewer embryos becomes more feasible and effective. In the routine, the embryonic selection is based on morphological criteria and characteristics of embryo development in order to infer its implantation potential (Ebner et al., 2003).
After controlled ovarian stimulation, approximately 50% of the embryos present chromosomal alterations (Munne et al., 1995). Then, the embryonic genetic evaluation is becoming increasingly used for the selection of euploid embryos for transfer. Blastocyst biopsy associated with chromosomal screening has been shown to be highly predictive of blastocyst developmental potential (Scott et al., 2012), increasing the chances of implantation by selection of euploid blastocysts for transfer in fresh (Scott et al., 2013) and frozen-thawed cycles (Schoolcraft and Katz-Jaffe, 2013).
In addition, preimplantation genetic screening (PGS) is indication for advanced maternal age (Schoolcraft et al., 2009), repeated implantation failure (Blockeel et al., 2008; Rubio et al. 2013), repeat miscarriage (Shahine and Lathi, 2014) and severe male factor (Harper and Sengupta, 2012). More recently, the use of PGS in cases of good prognosis for embryo selection in SET cycles has been proposed for both young and good prognosis patients (Yang et al., 2012), as well as for those in advanced age (Schoolcraft and Katz -Jaffe, 2013), with an important increase in the rate of embryo transfer associated with a reduction in the rates of multiple gestation (Ubaldi et al., 2015).
PGD was initially performed by in fluorescent in situ hybridization (FISH) technology from embryo biopsy on the third day of the development and analysis of one or two blastomeres by evaluating a limited number of chromosomes. The evolution of this technology led to the complete analysis of the 24 chromosomes by the comparative genome hybridization (CGH) platform associated with embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm. This approach is associated with higher rates of clinical gestation, improved embryo selection in SET cycles and decreasing multiple gestations in patients with good prognosis (Dahdouh et al., 2015). More recently, the next-generation sequencing (NGS) platform has been used and validated for embryonic genetic analysis in IVF, which is used for whole genome amplification (WGA), with the advantage of being a technology with potential to improve the embryonic chromosomal diagnosis in terms of robustness, automation and ability to detect aneuploidies (Fiorentino et al., 2014; Wells et al., 2014).
A recent study developed by the investigators group suggests that patients with good prognosis who perform SET in a fresh cycle and did not become pregnant, do not benefit from receiving a second transfer of two embryos, since the gestation rates are similar to those of patients who received one embryo in the second transfer, with the disadvantage of having a high incidence of multiple pregnancies. These results obtained in a retrospective study already indicate the advantages of performing SET in a sequential manner, promoting satisfactory gestation rates and safety for the mother and baby with regard to multiple gestation for patients with good prognosis (Monteleone et al. , 2016).
Based on these principles, the investigators consider that elective single embryo transfer (SET) associated with preimplantation genetic diagnosis by NGS (NGS + SET) for patients with good prognosis can result in higher success rates of IVF cycles and at the same time decreases multiple pregnancies, as well as maternal-fetal and neonatal risks inherited from this condition. This protocols is suppose to result in high rates of clinical gestation with less occurrence of abortions and greater overall success of the treatment. In order to prove this hypothesis, the investigators propose a study that compares the outcomes of IVF treatments in patients receiving the elective transfer of single embryo genetically evaluated by NGS (NGS + SET) and elective transference of two embryos genetically evaluated by NGS (NGS + DET). As a control, this study will include embryo transfer groups without preimplantation genetic diagnosis by NGS, that is, those that are selected for transfer only from morphological criteria as routine, being associated also the elective transference of one (SET) or two embryos (DET). In case of non-pregnancy in the first cycle of IVF, there will be subsequent transfers of one or two embryos respectively for each group until the remaining embryos are exhausted or until the patient reaches the gestation. The primary outcome will be the cumulative pregnancy rate per treatment cycle. This approach will allow to confirm or not the hypothesis that genetic analysis is effective in improving the embryo selection process and associated with SET will increase the rates of clinical gestation and decrease the rates of multiple gestations and miscarriages.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pedro Monteleone, MD, PhD
- Phone Number: +55 11 98354-9972
- Email: pedro@monteleone.med.br
Study Contact Backup
- Name: Tatiana Bonetti, PhD
- Phone Number: +55 11 984813107
- Email: tatibonetti76@gmail.com
Study Locations
-
-
SP
-
Sao Paulo, SP, Brazil
- Recruiting
- Faculdade de Medicina da Universidade de São Paulo (FMUSP)
-
Contact:
- Pedro AA Monteleone, PhD
- Email: pedro@monteleone.med.br
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Couples performing in vitro fertilization cycles using intracytoplasmic sperm injection
- Performing the first treatment cycle;
- Body Mass Index (BMI) of 18 to 30 kg / m2;
- Presence of both ovaries without evidence of significant abnormalities;
- Absence of any significant pathology of the endometrial cavity, such as polyps, fibroids larger than 4cm and hidrosalpinge;
- Normal ovarian reserve, determined by antral follicle count> 8 and FSH <12 mIU / mL;
- Use of fresh ejaculate or cryopreserved partner seminal sample
Exclusion Criteria:
Women presenting endometriosis degrees III and IV;
- Sperm used for fertilization from partner with severe oligozoospermia (<5 million sperm / ml);
- Women with associated systemic diseases or infectious diseases;
- Do not have at least two good quality blastocysts on the fifth day of development.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: SET
patients receiving the elective single embryo transfer
|
Transfer of single embryo
Other Names:
|
Experimental: SET+NGS
patients receiving the elective single embryo transfer evaluated genetically by NGS
|
Transfer of single embryo
Other Names:
This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform.
For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm
|
Active Comparator: DET
patients receiving the elective double embryo transfer
|
Transfer of two embryos
Other Names:
|
Experimental: DET+NGS
patients receiving the elective double embryo transfer evaluated genetically by NGS
|
This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform.
For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm
Transfer of two embryos
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cumulative pregnancy rate
Time Frame: 6 months
|
percentage of patients who become pregnant after transfer of embryos
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cycle cancellation rate
Time Frame: 1 month
|
percentage of cycles cancelled due to all embryos genetic alterated
|
1 month
|
multiple pregnancy rate
Time Frame: 6 months
|
percentage of patients who become pregnant of twins
|
6 months
|
live birth rates
Time Frame: one year
|
percentage of patients who had live birth
|
one year
|
transfers needed to achieve gestation
Time Frame: 6 months
|
number of embryos transfers needed to achieve gestation
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SET-NGS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
-
Turku University HospitalUniversity of TurkuCompleted
-
Centre Hospitalier René DubosCompletedDeciduitis; Complicating Pregnancy
Clinical Trials on Single embryo transfer
-
University Hospital Virgen de las NievesInstituto de Salud Carlos IIICompletedInfertility | Pregnancy, MultipleSpain
-
Vrije Universiteit BrusselTerminatedLive Birth Delivery RateBelgium
-
Reproductive Medicine Associates of New JerseyFerring PharmaceuticalsCompleted
-
Fundacion Para La Investigacion Hospital La FeUnknown
-
The University of Hong KongPeking University Third Hospital; Nanfang Hospital of Southern Medical University and other collaboratorsTerminated
-
Cairo UniversityRecruiting
-
Stanford UniversityCompleted
-
National Research Centre, EgyptNot yet recruiting
-
IgenomixUnknown